NextFin News - Seaport Therapeutics Inc., a clinical-stage biotechnology firm specializing in neuropsychiatric treatments, is seeking to raise up to $212.4 million in an initial public offering on the Nasdaq Global Market. According to a regulatory filing on Monday, the Boston-based company plans to offer 11.8 million shares priced between $16 and $18 each. At the top end of this range, Seaport would command a fully diluted market value of approximately $1.1 billion, marking a significant test for the biotech IPO window in early 2026.
The company, founded by PureTech Health and led by former Karuna Therapeutics executives, is betting on its proprietary "Glyph" platform. This technology is designed to bypass the liver’s first-pass metabolism by using the lymphatic system, potentially allowing for oral delivery of drugs that previously required injections or suffered from poor bioavailability. Its lead candidate, SPT-300, is an oral version of allopregnanolone being developed for major depressive disorder with anxious distress. While allopregnanolone is already clinically validated for postpartum depression, current treatments often require long intravenous infusions, a hurdle Seaport aims to clear with its oral prodrug.
Investor interest in the neuropsychiatry space has intensified following Bristol Myers Squibb’s $14 billion acquisition of Karuna Therapeutics in late 2023. Seaport’s leadership team includes Steven Paul, the former CEO of Karuna, and Daphne Zohar, the founder of PureTech. Their track record in bringing psychiatric drugs to market provides a layer of institutional credibility that often commands a premium in the biotech sector. However, the company remains in the clinical stage, with topline data for its Phase 2b BUOY-1 trial not expected until the first half of 2027, according to company disclosures.
The offering comes at a time when the broader biotech market is showing signs of selective recovery. While the appetite for high-growth, pre-revenue companies has been tempered by a higher-for-longer interest rate environment under U.S. President Trump’s administration, specialized platforms with "de-risked" biological targets—where the underlying molecule is already proven but the delivery mechanism is new—have found more favor. Seaport’s second candidate, SPT-320, follows a similar logic, applying the Glyph platform to agomelatine, an antidepressant already approved in Europe and Australia but hampered by liver toxicity concerns that Seaport hopes to mitigate.
Despite the pedigree of its management, the IPO carries the inherent risks of the drug development cycle. Clinical failures in psychiatry are notoriously frequent due to high placebo responses and the complexity of brain chemistry. Furthermore, the $212.4 million target is an increase from the preliminary $100 million placeholder filed earlier in April, suggesting either strong private demand or a strategic need to extend the company's cash runway deep into 2027. Goldman Sachs, TD Cowen, and Stifel are leading the underwriting for the debut, which will see the company trade under the ticker SPTX.
Explore more exclusive insights at nextfin.ai.
